Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda’s Osaka Plant Digitized with Cutting Edge Techs to Create Supply System for Its 1st Cell Therapy
Takeda Pharmaceutical’s Osaka Plant is now equipped with state-of-the-art digital technologies for the production of the company’s first cell therapy product Alofisel (darvadstrocel), after spending some two years for the completion of the manufacturing and supply system. Alofisel suspension for…
To read the full story
Related Article
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Takeda Showcases Manufacturing Line for Cell Therapy Alofisel
July 11, 2022
- Takeda Sets Up New Manufacturing Line for Alofisel at Osaka Plant
December 16, 2021
- Takeda Rolls Out Crohn’s Disease Cell Therapy Alofisel in Japan
December 1, 2021
BUSINESS
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Daiichi Starts Global PIII of Datroway in Adjuvant Urothelial Cancer
August 28, 2026
- FDA Accepts Kowa’s Glaucoma Drug K-911 for Review
August 28, 2026
- Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage
August 28, 2026
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…